東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Her-2 DNA vaccination and intratumor...

Wayne State University., Cancer Biology.

Linked to FindBook

Google Book

Amazon

博客來

Her-2 DNA vaccination and intratumoral immune modulation.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Her-2 DNA vaccination and intratumoral immune modulation./
Author:	Radkevich-Brown, Olga.
Description:	184 p.
Notes:	Adviser: Wei-Zen Wei.
Contained By:	Dissertation Abstracts International68-11B.
Subject:	Health Sciences, Immunology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3284371
ISBN:	9780549298496

Her-2 DNA vaccination and intratumoral immune modulation.
Radkevich-Brown, Olga.

Her-2 DNA vaccination and intratumoral immune modulation. - 184 p.

Adviser: Wei-Zen Wei.

Thesis (Ph.D.)--Wayne State University, 2007.

Her-2, human ErbB-2, is an oncogene and a tumor-associated antigen in several human cancers. Due to overexpression on tumor cells compared to normal tissues and intrinsic propensity to be presented to the immune cells and antibodies, it is also a target for cancer immunotherapy by Her-2 DNA vaccines. We established Her-2 transgenic (Tg) mouse model to mimic human immunological tolerance to Her-2. Her-2 Tg mice in three different backgrounds responded differently to Her-2 DNA vaccine suggesting genetic regulation of Her-2 vaccine efficacy in tolerant hosts. BALB Her-2 Tg mice were more responsive to Her-2 vaccine, while B6 Her-2 or F1 Her-2 Tg mice exhibited more profound tolerance. To overcome Her-2 tolerance, heterologous vaccine encoding rat ErbB-2, neu, was tested in Her-2 Tg mice. In less tolerant BALB Her-2 Tg mice, self Her-2 DNA vaccine was superior, while in B6 Her-2 Tg mice neither vaccine induced robust Her-2 immunity, suggesting that self Her-2 vaccine may be superior, particularly at inducing Her-2-specific Abs. To enhance immunogenicity of Her-2, we generated a panel of adjuvant-containing Her-2 DNA vaccines to overcome tolerance. Two constructs containing PADRE or tetC adjuvant sequences have shown enhanced Her-2 immunity and were selected for further testing. Tumors are vast reservoirs of antigens with the potential to be recognized by the immune system, but immunosuppressive tumor environment inhibits generation of anti-tumor immunity. To take advantage of this antigen reservoir, we expressed foreign antigen, tetC, by intratumoral DNA electroporation to make tumor microenvironment permissive to immune priming. Expression of SecTetC by intratumoral DNA electroporation combined with regulatory T cell depletion induced immune response to endogenous tumor antigens and inhibited tumor growth. With addition of IL-12 DNA electroporation, regression of established mammary tumors was achieved, and immunological memory to tumor antigens was established protecting against tumor recurrence.

ISBN: 9780549298496Subjects--Topical Terms:

1017716
Health Sciences, Immunology.

Her-2 DNA vaccination and intratumoral immune modulation.
LDR:03028nam 2200313 a 45 001 943705
005 20110520
008 110520s2007 ||||||||||||||||| ||eng d
020 $a 9780549298496
035 $a (UMI)AAI3284371
035 $a AAI3284371
040 $a UMI $c UMI
100 1 $a Radkevich-Brown, Olga. $3 1267742
245 1 0 $a Her-2 DNA vaccination and intratumoral immune modulation.
300 $a 184 p.
500 $a Adviser: Wei-Zen Wei.
500 $a Source: Dissertation Abstracts International, Volume: 68-11, Section: B, page: 7265.
502 $a Thesis (Ph.D.)--Wayne State University, 2007.
520 $a Her-2, human ErbB-2, is an oncogene and a tumor-associated antigen in several human cancers. Due to overexpression on tumor cells compared to normal tissues and intrinsic propensity to be presented to the immune cells and antibodies, it is also a target for cancer immunotherapy by Her-2 DNA vaccines. We established Her-2 transgenic (Tg) mouse model to mimic human immunological tolerance to Her-2. Her-2 Tg mice in three different backgrounds responded differently to Her-2 DNA vaccine suggesting genetic regulation of Her-2 vaccine efficacy in tolerant hosts. BALB Her-2 Tg mice were more responsive to Her-2 vaccine, while B6 Her-2 or F1 Her-2 Tg mice exhibited more profound tolerance. To overcome Her-2 tolerance, heterologous vaccine encoding rat ErbB-2, neu, was tested in Her-2 Tg mice. In less tolerant BALB Her-2 Tg mice, self Her-2 DNA vaccine was superior, while in B6 Her-2 Tg mice neither vaccine induced robust Her-2 immunity, suggesting that self Her-2 vaccine may be superior, particularly at inducing Her-2-specific Abs. To enhance immunogenicity of Her-2, we generated a panel of adjuvant-containing Her-2 DNA vaccines to overcome tolerance. Two constructs containing PADRE or tetC adjuvant sequences have shown enhanced Her-2 immunity and were selected for further testing. Tumors are vast reservoirs of antigens with the potential to be recognized by the immune system, but immunosuppressive tumor environment inhibits generation of anti-tumor immunity. To take advantage of this antigen reservoir, we expressed foreign antigen, tetC, by intratumoral DNA electroporation to make tumor microenvironment permissive to immune priming. Expression of SecTetC by intratumoral DNA electroporation combined with regulatory T cell depletion induced immune response to endogenous tumor antigens and inhibited tumor growth. With addition of IL-12 DNA electroporation, regression of established mammary tumors was achieved, and immunological memory to tumor antigens was established protecting against tumor recurrence.
590 $a School code: 0254.
650 4 $a Health Sciences, Immunology. $3 1017716
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0982
690 $a 0992
710 2 $a Wayne State University. $b Cancer Biology. $3 1267743
773 0 $t Dissertation Abstracts International $g 68-11B.
790 $a 0254
790 1 0 $a Fridman, Rafael $e committee member
790 1 0 $a Kong, Yi-chi $e committee member
790 1 0 $a Miller, Fred $e committee member
790 1 0 $a Wei, Wei-Zen, $e advisor
791 $a Ph.D.
792 $a 2007
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3284371